Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.450
+0.220 (9.87%)
At close: Aug 13, 2025, 4:00 PM
2.410
-0.040 (-1.63%)
Pre-market: Aug 14, 2025, 9:21 AM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $59.95M in the quarter ending June 30, 2025, with 92.73% growth. This brings the company's revenue in the last twelve months to $241.53M, up 636.99% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$241.53M
Revenue Growth
+636.99%
P/S Ratio
3.21
Revenue / Employee
$288,216
Employees
838
Market Cap
886.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IOVA News
- 6 days ago - Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - GlobeNewsWire
- 21 days ago - Here's why Iova stock surged 32% today and why the rally might not be over - Invezz
- 26 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
- 4 weeks ago - Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - PRNewsWire
- 4 weeks ago - Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma - GlobeNewsWire